NCT04872166: A Study of BTX-A51 in People With Advanced Solid Tumor or Non-Hodgkin Lymphoma

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MYC
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: All breast cancer patients are eligible for the dose escalation phase; Breast cancer patients are also eligible for the expansion phase if they have a tumor that expresses MYC
Exclusions: Patients with known central nervous system (brain) metastases- see trial for details

Comments are closed.

Up ↑